Search
Repligen Corp
RGENAdd to Watchlist
107.030USD
-6.570-5.78%
Close 05/13, 16:00（ET）Quotes delayed by 15 min
6.03BMarket Cap
117.17P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-5.78%
5 Days
-14.89%
1 Month
-12.69%
6 Months
-28.91%
Year to Date
-34.68%
1 Year
-18.64%
TradingKey Stock Score of Repligen Corp
Currency: USD Updated: 2026-05-12Key Insights
Repligen Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 18 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 182.17.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Repligen Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Repligen Corp Highlights
StrengthsRisks
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.75% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 738.26M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 124.36, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 65.93M shares, decreasing 3.85% quarter-over-quarter.
Held by Scotia Canadian Dividend Fund
Star Investor Scotia Canadian Dividend Fund holds 44.48K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.43.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
182.170
Target Price
+47.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Repligen Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Repligen Corp Info
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Ticker SymbolRGEN
CompanyRepligen Corp
CEOLoeillot (Olivier)
Websitehttps://www.repligen.com/
Related Instruments
+1.20%
-2.89%
+0.09%
-0.62%
+3.11%
-0.16%
+2.59%
-0.79%
-0.50%
+1.61%
+0.74%
-1.92%
-2.01%
+2.08%
-0.98%
-2.26%
+3.22%
-4.91%
+0.42%
-0.14%Popular Instruments
97.843
-0.269 (-0.27%)
298.870
+4.070 (+1.38%)
225.830
+5.050 (+2.29%)
4698.900
+11.370 (+0.24%)
494.090
+5.350 (+1.09%)
1447.230
-4.790 (-0.33%)
803.630
+37.050 (+4.83%)
402.620
+15.270 (+3.94%)
79389.990
-278.960 (-0.35%)
445.270
+11.820 (+2.73%)
